Lora Hailey, NP
Family · Chattanooga, TNNPI 1952651655
Payments from drug & device makers
Across 407 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Novartis$905
- Boehringer Ingelheim$710
- Johnson & Johnson$590
- E.r. Squibb & Sons, L.L.C.$537
- AstraZeneca$483
- plus $3K from 30 others
What the payments were for
- Travel & lodging$88111%
- Food & beverage$7,48489%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 31 | $1,906 |
| Novartis | 48 | $905 |
| Boehringer Ingelheim | 46 | $710 |
| Johnson & Johnson | 33 | $590 |
| E.r. Squibb & Sons, L.L.C. | 48 | $537 |
| AstraZeneca | 19 | $483 |
| United Therapeutics Corporation | 17 | $389 |
| Pfizer | 23 | $357 |
| Merck | 17 | $319 |
| Lexicon Pharmaceuticals, Inc. | 12 | $227 |
| Bayer | 17 | $217 |
| Amgen | 11 | $201 |
| Novo Nordisk | 12 | $185 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $170 |
| Baxter Healthcare | 6 | $141 |
| Alnylam Pharmaceuticals Inc. | 5 | $125 |
| Abbott | 5 | $102 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $85 |
| Amarin Pharma, Inc. | 4 | $80 |
| Kestra Medical Technology Services, Inc. | 4 | $77 |
| Irhythm Technologies, Inc. | 4 | $77 |
| Actelion Pharmaceuticals US, Inc. | 4 | $67 |
| Scpharmaceuticals Inc. | 3 | $61 |
| Lilly USA, LLC | 3 | $48 |
| Bridgebio Pharma, Inc. | 2 | $38 |
| Astellas Pharma US Inc | 2 | $35 |
| Inspire Medical Systems, Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Vital Connect, Inc | 1 | $33 |
| Preventice Services, LLC | 1 | $25 |
| Medtronic | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Biosense Webster, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$1,292
- XARELTO$125
- WATCHMAN Access System$119
How this compares
$8,379 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 795 | $655,013 |
| XareltoRivaroxaban | 212 | $189,425 |
| EntrestoSacubitril/Valsartan | 66 | $45,188 |
| JardianceEmpagliflozin | 45 | $37,688 |
| FarxigaDapagliflozin Propanediol | 49 | $36,501 |
| MultaqDronedarone Hcl | 13 | $17,880 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 53 | $16,553 |
| Dofetilide | 60 | $14,369 |
| Potassium Chloride | 31 | $11,443 |
| Flecainide Acetate | 147 | $8,013 |
| Propafenone Hcl ErPropafenone Hcl | 30 | $6,137 |
| Propafenone Hcl | 162 | $5,837 |
| Digoxin | 216 | $3,986 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 21 | $2,740 |
| Metoprolol Succinate | 216 | $2,561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $357 | $655,013795 claims |
| Johnson & JohnsonXarelto | $590 | $189,425212 claims |
| NovartisEntresto | $905 | $45,18866 claims |
| Boehringer IngelheimJardiance | $710 | $37,68845 claims |
| AstraZenecaFarxiga | $483 | $36,50149 claims |
| Sanofi-aventis U.S. LLCMultaq | $33 | $17,88013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Chattanooga
- Jennifer SparksChattanooga$120K
- Marcie BeasleyChattanooga$91K
- Amy RainsChattanooga$55K
- Bronte NaplesChattanooga$26K
- Ernest BrandtChattanooga$21K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.